These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

868 related items for PubMed ID: 15150106

  • 1. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
    Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH, Gores GJ.
    Cancer Res; 2004 May 15; 64(10):3517-24. PubMed ID: 15150106
    [Abstract] [Full Text] [Related]

  • 2. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
    Rosato RR, Dai Y, Almenara JA, Maggio SC, Grant S.
    Leukemia; 2004 Nov 15; 18(11):1780-8. PubMed ID: 15385934
    [Abstract] [Full Text] [Related]

  • 3. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR, Almenara JA, Coe S, Grant S.
    Cancer Res; 2007 Oct 01; 67(19):9490-500. PubMed ID: 17909059
    [Abstract] [Full Text] [Related]

  • 4. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H.
    Cell Death Differ; 2004 Jul 01; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells.
    Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ.
    Gastroenterology; 2005 Jun 01; 128(7):2054-65. PubMed ID: 15940637
    [Abstract] [Full Text] [Related]

  • 6. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R, Bedi A.
    Cancer Res; 2002 Aug 01; 62(15):4180-5. PubMed ID: 12154014
    [Abstract] [Full Text] [Related]

  • 7. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
    Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, Bhalla K.
    Cancer Res; 2004 Apr 01; 64(7):2580-9. PubMed ID: 15059915
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M, Mizuguchi J.
    J Orthop Res; 2003 Sep 01; 21(5):949-57. PubMed ID: 12919886
    [Abstract] [Full Text] [Related]

  • 10. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
    Aggarwal BB, Bhardwaj U, Takada Y.
    Vitam Horm; 2004 Sep 01; 67():453-83. PubMed ID: 15110190
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1.
    Wirth T, Kühnel F, Fleischmann-Mundt B, Woller N, Djojosubroto M, Rudolph KL, Manns M, Zender L, Kubicka S.
    Cancer Res; 2005 Aug 15; 65(16):7393-402. PubMed ID: 16103092
    [Abstract] [Full Text] [Related]

  • 13. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways.
    Suliman A, Lam A, Datta R, Srivastava RK.
    Oncogene; 2001 Apr 19; 20(17):2122-33. PubMed ID: 11360196
    [Abstract] [Full Text] [Related]

  • 14. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
    Nencioni A, Wille L, Dal Bello G, Boy D, Cirmena G, Wesselborg S, Belka C, Brossart P, Patrone F, Ballestrero A.
    Clin Cancer Res; 2005 Jun 01; 11(11):4259-65. PubMed ID: 15930365
    [Abstract] [Full Text] [Related]

  • 15. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis.
    Siegmund D, Hadwiger P, Pfizenmaier K, Vornlocher HP, Wajant H.
    Mol Med; 2002 Nov 01; 8(11):725-32. PubMed ID: 12520089
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
    Zhang L, Fang B.
    Cancer Gene Ther; 2005 Mar 01; 12(3):228-37. PubMed ID: 15550937
    [Abstract] [Full Text] [Related]

  • 17. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression.
    Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR, Ikegaki N, Brodeur GM, Phillips PC.
    Oncogene; 2000 Sep 21; 19(40):4604-10. PubMed ID: 11030149
    [Abstract] [Full Text] [Related]

  • 18. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K, Douglas L, Delaney A, Houghton JA.
    Clin Cancer Res; 2004 Oct 01; 10(19):6650-60. PubMed ID: 15475455
    [Abstract] [Full Text] [Related]

  • 19. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kazhdan I, Marciniak RA.
    Cancer Gene Ther; 2004 Oct 01; 11(10):691-8. PubMed ID: 15354201
    [Abstract] [Full Text] [Related]

  • 20. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP, Zisman A, Bonavida B.
    Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.